Rentschler Biopharma announces largest single investment at its headquarters in Germany
Construction of a new buffer media station in Laupheim
Advertisement
Rentschler Biopharma SE announced the construction of a new state-of-the-art buffer media station at its company headquarters in Laupheim. The new facility aims to further increase production efficiency and modernize the site, ensuring that the evolving needs of clients and patients are anticipated and fully met, both now and in the future.
"This investment underscores our commitment to the long-term development of our Laupheim site, a key part of Germany’s biotechnology landscape. This expansion will strengthen our competitive position in one of the world’s fastest-growing industries. As a company with 150 years of tradition, Rentschler Biopharma has always embraced forward-looking, strategic planning, enabling us to grow sustainably as an independent family-owned company. I would like to thank all colleagues involved in the planning and execution of this significant project," said Benedikt von Braunmühl, Chief Executive Officer of Rentschler Biopharma. “Government support for a German national pharmaceutical strategy is an important signal for the industry as a whole. While our focus remains on strengthening global partnerships, this investment in our German site plays a crucial role in ensuring supply chain reliability and advancing our long-term growth strategy."
The state-of-the-art, four-story buffer media station, covering 34,000 square meters, is set to be operational by 2028. The new facility will be seamlessly integrated with the existing infrastructure, offering faster and more efficient processes, as well as ergonomically designed workstations, providing an optimal working environment for employees. The new building, along with all technical systems, will meet the highest quality and automation standards, and, through its state-of-the-art equipment, support Rentschler Biopharma's environmental and sustainability goals.
“As a CDMO, it is our responsibility to support our clients in transforming innovative ideas into life-saving biopharmaceuticals. Patients with rare and severe diseases rely on the therapies we develop and manufacture in partnership with our clients. This project is therefore not just an investment in our infrastructure, it is a fundamental part of our work, creating value sustainably for the benefit of our clients and for patients and ensuring the availability of therapeutics in Germany and globally. With the new buffer media station, we are making a significant contribution to operational excellence, enabling us to respond rapidly to growing client demands. We are also creating a more ergonomic work environment for our employees and positioning our site for future success,” added Christiane Bardroff, Chief Operating Officer of Rentschler Biopharma.
The new facility will include three media tanks and six buffer tanks, providing sufficient space and capacity for the production of buffer solutions and media. Buffer and media preparation will be carried out in separate areas to ensure the highest standards of hygiene and safety. In addition, the facility will be connected to the in-house logistics system and the piping system for upstream and downstream processes.
Detailed planning for the new building has already begun, and construction is scheduled to start in spring 2025. Completion and operational launch are planned by the end of 2027, allowing the full potential of the new buffer media station to be realized by 2028.
Other news from the department manufacturing
These products might interest you
LowCross-Buffer® by CANDOR Bioscience
Improve Accuracy of Your ELISAs!
LowCross-Buffer
Liquid Plate Sealer by CANDOR Bioscience
Protection for Antibodies and Antigens Coated on Plates
For Long-Term Stability of Antibodies Coated on ELISA-Plates, Affinity Columns and Other Surfaces
Most read news
More news from our other portals
Last viewed contents
Merck Invests €70 million to Expand ADC Manufacturing for Novel Cancer Therapies - Triples manufacturing capacity to meet increased global demand for antibody-drug conjugates (ADCs)
Lonza expands bioconjugation in Visp with two additional manufacturing suites
Daiichi Sankyo's investments in cancer drugs are taking shape - From Bavaria to the world: Daiichi Sankyo transfers technology for the development and production of antibody-drug conjugates to Germany
Waldner: Ground-breaking for new powder coating plant
Roche lays the foundation for the diagnostics production of the future in Germany - Investment of more than 600 million euros in a high-tech production center - Roche's largest single investment in Germany to date
ProBioGen expands protein and virus manufacturing to drive continued growth
Enduro Genetics raises €12 million to unlock the future of scalable bioproduction - Patented cell reprogramming technology "addicts" cells to high production and integrates seamlessly into any microbial bioproduction host
Sensirion opens additional production building in Debrecen
Frank Winkler receives the Brain Prize 2025 - The interaction between the nervous system and cancer is increasingly coming into focus
CorTec Welcomes Dr. Frank Desiere as Chief Executive Officer - A Strengthened Leadership Team to Accelerate Growth and Innovation
New Leadership at Andreas Hettich GmbH - After 20 years of successful leadership by the Eberle family, the Hettich Group is entering a new, forward-looking phase
